Approximately one third of congenital heart defects affect the heart valves [1]. When valve repair is not feasible, heart valve replacement becomes necessary. In infants, current valve replacement options include homograft, autografts, mechanical valves and bioprosthetics. Each of these treatment modalities presents significant limitations in the pediatric population.

Despite their widespread use, homografts are acellular and do not retain viable cells, thereby lacking potential for somatic growth [2]. This limitation commits infants to serial valve replacements since they outgrow their prosthesis until an adult-sized valve can be implanted [3]. Mechanical valves offer durability but do not grow and require life-long anticoagulation due to thromobogenicity [4]. These pose significant risk in infants like thromboembolic events [5] and requires risky re-operations to replace outgrown valve [6]. Bioprosthetic valves avoid anticoagulation but suffer from rapid structural degeneration in young patients, an irreversible process leading to valve failure requiring re-operations [7]. Additionally, mechanical and bioprosthetic valves are not manufactured in sizes suitable for neonates, necessitating the exclusive use of homografts (live or cryopreserved) in this population [8].

In pediatric patients, Ross procedure is an attractive option because the autograft is viable, capable of growth, and potentially decreases the need for redo aortic valve replacements [9]. However it is not without drawback, problem that plagues Ross procedures involves a double-valve intervention, introducing the risk of complications at two valve sites [10]. Autograft dilation, regurgitation, and eventual failure are known long-term concerns, particularly when the pulmonary valve is exposed to systemic pressures [11]. Moreover, the need for homograft or conduit replacement in the right ventricular tract remains a major limitation, as these substitutes do not grow and frequently require re-intervention during follow-up [12].

More recently, partial heart transplantation has been proposed to deliver growing heart valve substitutes. While it offers living tissue with growth capacity, this strategy remains constrained by donor availability and necessitates lifelong immunosuppression [13]. Autologous pulmonary valve reconstruction using right atrial appendage has shown early success [14] but require long-term follow-up studies to assess durability and effectiveness [15].

To overcome these challenges, we have developed a simple and reproducible surgical technique for semilunar valve replacement with autologous arterial trunk tissue. This technique avoids the need for immunosuppression, anticoagulation or donor tissue. Most importantly, it uses patient’s own viable arterial tissue, which has a potential for somatic growth. Compared to the Ross procedure, it avoids manipulation of two valve positions and the associated risks, offering a single-site, growth-capable solution that may reduce surgical burden and improve long-term outcomes. Additionally, the biomechanical properties of arterial trunk tissue may offer superior durability and functional integration in semilunar valve positions.

The technique was developed using 2 heart blocks from domestic swine of unknown gender obtained from a local abattoir. Only specimens without anatomical abnormalities grossly were included. As the study was limited to ex vivo experiments. Institutional Animal Care and Use Committee (IACUC) approval was not required.

We explored the feasibility for harvesting aortic or pulmonary arterial tissue, assessing structural integrity. Valves were screened for regurgitation using static pressurization of the aortic root with water to identify.

Among the possible vascular tissue, ascending aorta and main pulmonary artery are identified as the most suitable for graft harvesting. We prefer the pulmonary trunk due to ease of harvest and reconstruction. Preoperative imaging can be used to assess the aortic root height, annular size, and the dimensions (length and diameter) of the available donor arterial trunk to ensure anatomical adequacy. This is particularly important with the pulmonary artery as the available tube for harvest is limited by the distance between the sinotubular junction, and the branch pulmonary arteries (particularly the right pulmonary artery) take off. The height of the valve must at least equal to the annular diameter of the valve being replaced, or 10 mm height in early childhood.

Intraoperatively, the donor vessel is extensively mobilized for a tension-free anastomosis after autograft procurement. Routine venous cannulation is performed via the right atrium using a two-stage cannula, and a left ventricular vent introduced via the right superior pulmonary vein to prevent distention and improve exposure. Cardiopulmonary bypass is initiated, and the pulmonary arterial trunk harvested on a beating heart (Fig. 1a). If using the ascending aorta, the proximal arch needs to be cannulated to preserve room for tissue harvest and reconstruction. Antegrade cardioplegic is delivered to induce cardiac arrest. The aorta is opened transversely just cephalad of the sinotubular junction (STJ). In patients with limited access (small aortic roots) this incision can be extended into the non-coronary sinus. The native aortic valve is excised and the aortic annulus is again measured. If the arterial trunk is larger in diameter than the measured aortic annulus, it can now be downsized using longitudinal plication to achieve an optimal fit or downsizing the tube of tissue over an aortic annulus sized hegar dilator. The tailored harvested trunk is now inverted and intussuscepted into the left ventricular outflow tract for easy, and unobstructed, suturing of the base to the aortic annulus using a running suture technique (Fig. 1b). If an incision is made into the root, this is closed to the STJ. The trunk is now pulled up with the result that the adventitia towards the aortic sinuses. Two vertical anchoring sutures are placed at opposite commissures to fix the graft to the STJ creating commissures (Fig. 1c). These commissures are chosen to bisect the circumference between the coronary arteries. The arterial trunk construct now functions as a telescoped bicuspid aortic valve (Fig. 1d and Fig. 2).

This is followed by aortic reconstruction. The posterior half of the pulmonary bifurcation is now anastomosed to the pulmonary arterial STJ. If necessary, the anterior portion of the vessel is reconstructed with patch material, to relieve anastomotic tension (Fig. 1e).

Valve stability is ensured through two mechanisms: (1) circumferential running suture fixation of the graft base to the aortic annulus, and (2) vertical anchoring sutures placed at opposing commissures at the STJ. These sutures will help prevent migration, rotation or prolapse of the graft.

While the technique is developed using domestic swine heart blocks, it could be adapted for any other large animal models and potentially human applications. The flexibility in modifying the arterial trunk diameter and tailoring the anchor points allows for use in a range of anatomical variations, including pediatric and adult populations. While we discuss harvesting a tube for ease of reproducibility, a patch of pulmonary arterial tissue can also be harvested and shaped into a tube for creating this type of bicuspid valve.

Semilunar valve intervention in infants is fraught with problems due to lack of ideal replacement options [16]. Existing prosthetic vales—mechanical, bioprosthetic, homografts—lack growth potential [2] and are often associated with considerable morbidity, necessitating reoperations or lifelong anticoagulation [5]. The Ross procedure, though advantageous in terms of autologous tissue use and growth potential, carries risk of autograft failure [10,11].

In contrast, our proposed approach uses autologous vascular tissue, capitalizing on its direct perfusion from the blood stream and intrinsic growth potential. We have developed a novel surgical technique, to transform arterial tissue into a bicuspid semilunar valve with good hemodynamic outcomes ex-vivo. We note that autologous vascular tissue can also be employed with other more complex surgical techniques, such as leaflet reconstructions and the Ozaki technique. Compared to aforementioned alternatives, our telescoping arterial trunk technique is relatively simple, reproducible and adaptable, particularly in context of small annuli where annular enlargement is often necessary. It does not rely on foreign material or fixed pericardial tissue which may calcify or degenerate over time.

Despite its promise, translating this technique into clinical practice will require careful consideration and faces multiple challenges. First, while the procedure is technically straightforward in the ex-vivo setting, in-vivo application may introduce complexities related to anatomical variability, tissue handling and surgical exposure in the neonates and infants. Second, the long-term durability and functional performance of the telescoped valve under systemic pressures remain to be seen.

Although the use of autologous tissue eliminates concerns regarding immunogenicity and graft rejection, it raises concerns related to tissue harvesting. The use of the vascular tissue must be balanced with the risk of compromising donor vessel integrity and future vessel growth. The altered environment and function of the autologous graft may elicit unforeseen biological responses. Moreover, post-operative complications such as valve insufficiency and outflow tract obstruction due to telescoped valve immobility need to be closely monitored. These considerations will be the focal point for future in-vivo studies.

We are currently initiating preclinical in-vivo studies to evaluate the long-term functionality, durability and growth potential of the telescoping arterial trunk valves. If successful this approach could represent an alternative in semilunar valve replacement for pediatric patients, one that aligns with the unique physiological needs of growing children.